AGMB · AgomAb Therapeutics NV American Depositary Shares
View on chartInsiders & Stakes
| Knotnerus Tim Jasper Chief Executive Officer | ▲ Buy | Open Market | 21,823 Shares held | 10/6/2026 | View profile |
| David R. Epstein Director | ▲ Buy | Open Market | 15,000 Shares held | 10/8/2026 | View profile |
| Kemula Pierre Thadee Victor Chief Financial Officer | ▲ Buy | Open Market | 10,000 Shares held | 10/6/2026 | View profile |
Transaction History
| David R. Epstein | ▲ Buy | Open Market | 5,000 | $45K | 10/8/2026 |
| David R. Epstein | ▲ Buy | Open Market | 5,000 | $44K | 10/6/2026 |
| Kemula Pierre Thadee Victor | ▲ Buy | Open Market | 3,000 | $26K | 10/6/2026 |
| Kemula Pierre Thadee Victor | ▲ Buy | Open Market | 5,000 | $43K | 10/6/2026 |
| Kemula Pierre Thadee Victor | ▲ Buy | Open Market | 2,000 | $17K | 10/6/2026 |
| Knotnerus Tim Jasper | ▲ Buy | Open Market | 5,000 | $44K | 10/6/2026 |
| David R. Epstein | ▲ Buy | Open Market | 5,000 | $43K | 10/5/2026 |
| Knotnerus Tim Jasper | ▲ Buy | Open Market | 6,000 | $51K | 10/5/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Agomab Reports Favorable Safety Data in Phase 2A Crohn's Trial
Agomab Therapeutics shared results from the 48-week open-label extension of its Phase 2A STENOVA trial for severe Crohn's disease. The company noted that the safety and tolerability profile of ontunisertib remained favorable through up to 60 weeks of treatment. Additionally, the annualized rate of FSCD-related events was reported at 3%. This clinical update provides context for the stock's current trading levels near its 52-week low.
Agomab Reports Favorable Safety Data in Phase 2A Crohn's Trial. Agomab Therapeutics shared results from the 48-week open-label extension of its Phase 2A STENOVA trial for severe Crohn's disease. The company noted that the safety and tolerability profile of ontunisertib remained favorable through up to 60 weeks of treatment. Additionally, the annualized rate of FSCD-related events was reported at 3%. This clinical update provides context for the stock's current trading levels near its 52-week low.